Accessibility Menu
CalciMedica logo

CalciMedica(NASDAQ) CALC

Current Price$0.74
Market Cap$22.00MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2023)-88%
5 Year-99%
1 Year-83%
1 Month-11%
CalciMedica last closing stock price
MetricPriceDate
Last closeUSD 0.722026-07-23
CalciMedica stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+3.16%USD 0.692026-07-16
1 month-10.88%USD 0.802026-06-23
3 month+22.48%USD 0.582026-04-24
Year to date-89.14%USD 6.592025-12-31
1 year-82.95%USD 4.202025-07-23
3 year-80.11%USD 3.602023-07-24
5 year-98.76%USD 57.822021-07-23
Since inception-88.24%USD 6.332023-03-21

CalciMedica Financials at a Glance

Market Cap

$22.00MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$19.54M

EPS (TTM)

-$1.31

P/E Ratio

-0.55

Dividend

$0.00

Beta (Volatility)

0.50 (Low)

Price

$0.74

Volume

4,695

Open

$0.75

Previous Close

$0.72

Daily Range

$0.70 - $0.75

52-Week Range

$0.46 - $7.20

Estimated Earnings Date

Aug 11, 2026

CALC News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About CalciMedica

CalciMedica develops medicines for severe inflammatory diseases with few treatment options. Its main drug aims to help people with sudden pancreas or kidney problems. The company’s work targets patients facing life-threatening inflammation in hospitals.

What’s in the Medicine Cabinet?

  • Auxora: An intravenous drug in trials for acute pancreatitis, kidney injury, and rare pediatric conditions; no sales yet.
  • CM5480: Early-stage drug candidate for high blood pressure in lung arteries; not yet in human trials.
  • Oral CRAC Inhibitors: Preclinical research for chronic diseases like arthritis and asthma; not yet generating revenue.

Growth Spurts and Growing Pains

  • Completed Phase 2b trial for Auxora in acute pancreatitis in 2025.
  • Discontinued kidney injury trial in January 2026 after safety review.
  • Raised $20.4M in private placement (2024), $10.2M in public offering (2024), and $10M loan (2025).
  • Engaged with FDA in 2026 to plan next steps for main drug approval.
  • Exploring partnerships for future drug development and commercialization.

Why CalciMedica Catches the Eye

The company uses a unique approach to block calcium channels that drive inflammation. Its drugs are designed for fast action in emergencies, aiming to protect organs from damage. CalciMedica holds patents worldwide and focuses on rare, severe diseases with few competitors.

Five Things You Need to Know

  • No revenue in 2023, 2024, or 2025; still pre-commercial.
  • Net loss was $29.6M in 2025, up 116% from 2024.
  • Cash position was $13.0M at end of 2025; runway into Q4 2026.
  • Operating expenses reached $23.1M in 2025, with R&D at $15.2M.
  • Company has 14 employees and a market cap of $8.68M as of 2025.

Bottom Line

CalciMedica remains focused on developing hospital treatments for acute inflammation. The company faces ongoing losses and funding needs as it advances its drug pipeline.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

16

CEO

Rachel Anne Leheny, PhD

Website

www.calcimedica.com

Headquarters

La Jolla, CA 92037, US

CALC Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

4092.98%

Return on Capital

-755.84%

Return on Assets

-227.02%

Earnings Yield

-1.82%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$22.00MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

30.74M

Volume

4.70K

Avg. Volume

1.28M

Financials (TTM)

Gross Profit

-$7.00K

Operating Income

-$22.24M

EBITDA

-$18.21M

Operating Cash Flow

-$21.16M

Capital Expenditure

-$19.00K

Free Cash Flow

-$21.18M

Cash & ST Invst.

$8.16M

Total Debt

$0.00

CalciMedica Performance Analysis

CalciMedica annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
CalciMedica sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
CalciMedica annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1,556.186478.3%
20232023-12-31USD -7.66-99.5%
20242024-12-31USD -1.22-84.1%
20252025-12-31USD -1.9761.7%
CalciMedica sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-11.1%
Q32025-09-30-30.0%
Q42025-12-31-38.5%
Q12026-03-31141.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$7.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$22.00MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.38M

N/A

Employees

16

N/A

Net Income

$4.98M

+198.7%

EBITDA

$5.30M

+215.8%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$8.16M

-66.8%

Total Debt

$0.00

-100.0%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

-100.0%

Short Term Debt

$0.00

N/A

Return on Assets

-2.27%

N/A

Return on Invested Capital

-6.75%

N/A

Free Cash Flow

-$4.86M

+0.6%

Operating Cash Flow

-$4.86M

+0.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
TVRDTvardi Therapeutics, Inc.
$2.52-1.76%
RNXTRenovoRx, Inc.
$0.86+0.30%
LTRNLantern Pharma Inc.
$2.79-2.79%
RVPHReviva Pharmaceuticals Holdings, Inc.
$0.49+8.86%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.29-0.06%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$44.16+0.02%
CLFCleveland-Cliffs
$11.11+0.01%
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$32.13-0.12%

Questions About CALC

What is the current price of CalciMedica?

CalciMedica is trading at $0.74 per share.

What is the 52-week range for CalciMedica?

Over the past 52 weeks, CalciMedica has traded between $0.46 and $7.20.

How much debt does CalciMedica have?

As of the most recent reporting period, CalciMedica reported total debt of $6.70M.

How much cash does CalciMedica have on hand?

CalciMedica reported $8.16M in cash and cash equivalents in its most recent financial results.

What is CalciMedica’s dividend yield?

CalciMedica does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services